Januvia (sitagliptin) and Mounjaro (tirzepatide) are both incretin-based therapies used to manage type 2 diabetes, but taking Januvia and Mounjaro together is not recommended in UK clinical practice. Whilst there is no absolute contraindication, combining these medications offers little additional benefit and may increase the risk of side effects. Mounjaro, a potent dual GIP/GLP-1 receptor agonist, provides comprehensive incretin-based glucose control that encompasses and exceeds the effects of Januvia, a DPP-4 inhibitor. NICE guidance supports using one incretin-based therapy at a time, and if Mounjaro is initiated, Januvia is typically discontinued. Always consult your GP or diabetes specialist before making any changes to your medication regimen.

Can You Take Januvia and Mounjaro Together?

The combination of Januvia (sitagliptin) and Mounjaro (tirzepatide) is not recommended in clinical practice, and UK prescribing guidance advises against their concurrent use. Both medications work on the incretin system, which regulates blood glucose levels in people with type 2 diabetes, but through different mechanisms. While there is no absolute contraindication preventing their use together, the therapeutic benefit of combining them is limited, and doing so may increase the risk of adverse effects without providing meaningful additional glycaemic control.

Januvia belongs to a class of medications called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors), while Mounjaro is a dual GIP/GLP-1 receptor agonist. Because Mounjaro already provides potent incretin-based glucose control, adding Januvia—which works by preserving naturally occurring incretins—offers little to no added benefit. Clinical trials of GLP-1-based therapies have typically excluded patients taking DPP-4 inhibitors due to overlapping mechanisms of action.

If you are currently prescribed Januvia and your doctor is considering starting Mounjaro, the usual approach is to discontinue Januvia before initiating Mounjaro. This avoids unnecessary polypharmacy and reduces the potential for side effects. NICE guidance (NG28) on type 2 diabetes management supports stepwise treatment escalation, with GLP-1-based therapies like Mounjaro typically reserved for patients who have not achieved adequate control with other agents. Always consult your GP or diabetes specialist before making any changes to your medication regimen, as individual circumstances vary and professional guidance is essential.

How Januvia and Mounjaro Work Differently

Understanding the distinct mechanisms of action of Januvia and Mounjaro helps clarify why combining them is generally unnecessary. Januvia (sitagliptin) is a DPP-4 inhibitor that works by blocking the enzyme dipeptidyl peptidase-4. This enzyme normally breaks down incretin hormones—specifically GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)—which are released by the gut in response to food. By inhibiting DPP-4, Januvia prolongs the activity of these naturally occurring incretins, leading to increased insulin secretion when blood glucose is elevated and reduced glucagon release. The result is improved glycaemic control with a low risk of hypoglycaemia. Januvia is taken orally once daily and is generally well tolerated.

Mounjaro (tirzepatide), by contrast, is a novel injectable medication that acts as a dual agonist of both GIP and GLP-1 receptors. Rather than preserving endogenous incretins, Mounjaro directly stimulates these receptors with a synthetic peptide. This dual action produces a more potent effect on glucose regulation, insulin secretion, and glucagon suppression. Additionally, Mounjaro has significant effects on appetite and gastric emptying, leading to substantial weight loss in many patients—an effect not typically seen with DPP-4 inhibitors. Mounjaro is administered via subcutaneous injection once weekly.

The key difference lies in potency and scope of action. Whilst Januvia modestly enhances the body's own incretin response, Mounjaro delivers a powerful, direct receptor activation that produces greater reductions in HbA1c and body weight, as demonstrated in clinical trials and documented in the EMA's European Public Assessment Report (EPAR). Because Mounjaro's effects encompass and exceed those of Januvia, adding a DPP-4 inhibitor provides negligible additional benefit. NICE guidance (NG28) supports using one incretin-based therapy at a time, with GLP-1-based therapies preferred when more intensive glucose and weight management is required.

Potential Risks of Combining Januvia with Mounjaro

Whilst the combination of Januvia and Mounjaro is not associated with severe drug interactions, there are several reasons why concurrent use is discouraged. The primary concern is lack of additional efficacy—clinical studies have not demonstrated meaningful improvements in glycaemic control when DPP-4 inhibitors are added to GLP-1-based therapies. This means patients may be exposed to additional medication costs and potential side effects without therapeutic gain.

Gastrointestinal side effects are common with Mounjaro, particularly during dose escalation. These include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. Whilst Januvia is generally well tolerated, adding it to Mounjaro does not reduce these side effects and may, in theory, contribute to gastrointestinal disturbance in some individuals. Patients already struggling with nausea from Mounjaro may find additional medications burdensome.

Both medications carry warnings about pancreatitis risk. The UK SmPCs for both Januvia and Mounjaro advise discontinuing treatment if pancreatitis is suspected. If you experience severe, persistent abdominal pain (which may radiate to your back), with or without vomiting, stop taking the medication and seek urgent medical attention via NHS 111 or 999 if symptoms are severe.

There is also a risk of gallbladder problems with Mounjaro. Contact your doctor promptly if you experience symptoms such as right upper abdominal pain, fever, or yellowing of the skin or eyes.

When either medication is used alongside insulin or sulphonylureas, hypoglycaemia risk may increase. If Mounjaro is added to these medications, your doctor may need to reduce their doses to prevent low blood sugar. Patients should be familiar with hypoglycaemia symptoms—such as sweating, tremor, confusion, and palpitations—and know how to manage them.

If you experience any suspected side effects from your diabetes medications, you can report them through the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).

What Your Doctor Needs to Know Before Prescribing Both

If your healthcare provider is considering any changes to your diabetes medication regimen, a thorough clinical assessment is essential. Before prescribing Mounjaro—especially if you are already taking Januvia—your doctor will need to review several key factors to ensure safe and effective treatment.

Current glycaemic control is a primary consideration. Your doctor will assess recent HbA1c levels, fasting glucose readings, and any patterns of hypo- or hyperglycaemia. NICE guidance recommends GLP-1-based therapies for adults with type 2 diabetes who have inadequate control despite treatment with metformin and other oral agents, with individualised targets based on your specific circumstances. If Mounjaro is deemed appropriate, discontinuing Januvia is usually advised to avoid redundancy.

Medical history is equally important. Your doctor should know if you have a history of:

• Pancreatitis (acute or chronic)—both medications carry warnings about pancreatitis risk

• Severe gastrointestinal disease, including gastroparesis, which may be exacerbated by GLP-1-based therapies

• Renal impairment—sitagliptin requires dose adjustment based on eGFR, while tirzepatide does not require dose adjustment, though caution is advised with dehydration

• Thyroid disease—Mounjaro's UK SmPC notes that rodent studies showed an increased incidence of thyroid C-cell tumours, though the relevance to humans is unknown. Clinical vigilance is advised.

Current medications must be reviewed for potential interactions. Mounjaro slows gastric emptying, which can affect the absorption of oral medications. Importantly, if you use oral contraceptives, Mounjaro may reduce their effectiveness. Additional contraceptive methods are recommended for 4 weeks after starting Mounjaro and after each dose increase.

Finally, discuss your treatment goals and preferences. Mounjaro offers significant weight loss benefits, which may be desirable for many patients with type 2 diabetes and obesity. However, it requires weekly injections and may cause gastrointestinal side effects. Open communication about expectations, tolerability, and lifestyle factors helps ensure the chosen regimen is both effective and sustainable.

Alternative Treatment Options for Type 2 Diabetes

Type 2 diabetes management in the UK follows a stepwise approach aligned with NICE guidelines (NG28), which emphasise individualised treatment based on patient characteristics, comorbidities, and treatment goals. If Januvia and Mounjaro together are not appropriate, several alternative strategies can provide effective glycaemic control.

Metformin remains the first-line oral agent for most adults with type 2 diabetes, unless contraindicated. It improves insulin sensitivity, reduces hepatic glucose production, and has a favourable safety profile with low hypoglycaemia risk. Metformin is also associated with modest weight loss or weight neutrality, making it suitable for long-term use.

SGLT2 inhibitors (sodium-glucose co-transporter-2 inhibitors) such as dapagliflozin, empagliflozin, or canagliflozin are increasingly favoured, particularly for patients with established cardiovascular disease, heart failure, or chronic kidney disease. NICE guidance now recommends these agents can be used first-line in these conditions, regardless of metformin tolerance. These agents promote urinary glucose excretion, leading to reductions in HbA1c, body weight, and blood pressure, with proven cardiovascular and renal protection.

GLP-1 receptor agonists like semaglutide (Ozempic, Rybelsus), dulaglutide (Trulicity), and liraglutide (Victoza) are recommended when additional glucose lowering and weight loss are needed. Mounjaro (tirzepatide), as a dual GIP/GLP-1 receptor agonist, represents a distinct class with particularly potent effects on both glucose control and weight. These agents vary in dosing frequency (daily to weekly) and route of administration (injectable or oral).

For patients requiring further intensification, basal insulin (such as insulin glargine or insulin degludec) can be added to oral or injectable agents. Insulin therapy provides flexible, potent glucose control but requires careful dose titration and patient education to minimise hypoglycaemia risk.

Sulphonylureas (e.g., gliclazide) and thiazolidinediones (e.g., pioglitazone) are older oral agents still used in certain situations, though they are less commonly prescribed due to side effect profiles, including weight gain and hypoglycaemia risk.

Your diabetes care team—comprising your GP, practice nurse, and potentially a diabetes specialist nurse or consultant—will work with you to tailor treatment to your individual needs. Regular monitoring, lifestyle modification (including diet and physical activity), and patient education remain cornerstones of effective diabetes management. If you have concerns about your current regimen or are experiencing side effects, contact your GP surgery to arrange a medication review.

Frequently Asked Questions